

Antimicrobial susceptibility and genotypes of invasive staphylococcal isolates

顏佑珊、劉淑瑛、邱政洵

E-mail: 374865@mail.dyu.edu.tw

ABSTRACT

Background Staphylococcus aureus is an important causative agent for a wide variety of clinical infections. The aim of this study was to analyze antimicrobial susceptibilities and genotypes of methicillin-resistant *S. aureus* (MRSA), methicillin-sensitive *S. aureus* (MSSA) and coagulase-negative Staphylococcus (CoNS) that caused invasive infections. Methods A total of 198 clinical MRSA strains, 51 clinical MSSA strains and 48 clinical CoNS strains isolated from blood and their clinical presentations in Chang Gang Memorial Hospital in 2010 were collected. E-test strips were applied to determine minimum inhibitory concentration (MIC), and polymerase chain reaction (PCR) was used to detect staphylococcal cassette chromosome mec (SCCmec) types and the presence of Pantone-Valentine leukocidin (PVL) gene and multilocus sequencing typing (MLST). Antimicrobial MIC of MRSA was tested for the correlation with SCCmec types, PVL and MLST. Results The MIC ranges of vancomycin, teicoplanin, linezolid and daptomycin among all MRSA were 0.75-6, 0.38-12, 0.5-3, and 0.09-2 μ g/L respectively, whereas those among heterogeneous vancomycin-intermediate *S. aureus* (hVISA) were 2-6, 2-6, 1-1.5, and 0.5-1.5 μ g/L respectively. The MIC ranges of vancomycin and daptomycin among MSSA and CoNS were 1-1.5, 0.125-0.5 and 0.75-3, 0.125-2 μ g/L respectively. Among MRSA isolates, 114 belonged to the types of SCCmec I, II, III, and 84 to the types of SCCmec IV and V. Our studies indicated that SCCmec I, II, III was present in the HA-MRSA and SCCmec IV, V in the CA-MRSA in Taiwan, as revealed in previous studies that the SCCmec I, II, III commonly found in hospital-acquired MRSA (HA-MRSA), and SCCmec IV, V conversely in community-acquired MRSA (CA-MRSA). We found that only 24 CA-MRSA isolates (8.78%) contained PVL genes. In addition, the major MLST types among HA-MRSA and CA-MRSA were ST239 and ST59, respectively. Noteworthily, ciprofloxacin resistance was found among all MRSA with ST45 but not ST59; however, the pattern of antimicrobial resistance among them was not correlated to SCCmec type and PVL gene. Conclusions PVL-negative MRSA isolates were resistant to more antimicrobial drug classes than PVL-positive. Daptomycin still has effective activity against the current *S. aureus* clinical isolates, include MRSA. Ciprofloxacin-resistant isolates found in Taiwan all belonged to ST45. HA-MRSA showed higher antimicrobial resistance than CA-MRSA; however, CA-MRSA caused higher morbidity rates than HA-MRSA. Thus, MRSA is still a growing concern to public health.

Keywords : MRSA、MSSA、CoNS、SCCmec、PVL、MLST、MIC、vancomycin、teicoplanin、linezolid、daptomycin、ST45

Table of Contents

封面內頁 簽名頁 中文摘要	iii 英文摘要
v 誌謝	vii 目錄
viii 圖目錄	xi 表目錄
xii 1. 前言 1.1 金黃色葡萄球菌 (<i>Staphylococcus aureus</i>)	1 1.2 Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) 3
1.2.1 Hospital-acquired MRSA (HA-MRSA) 4	1.2.2 Community-associated MRSA (CA-MRSA) 5
1.2.3 HA-MRSA與CA-MRSA的差異性 6	1.2.3.1 Staphylococcal cassette chromosome mec (SCCmec) 6
1.2.3.2 Pantone-Valentine Leukocidin (PVL) 7	1.2.3.3 Phenol-Soluble Modulin (PSM) 7
1.3 Coagulase-negative <i>Staphylococcus</i> (CoNS) 7	1.4 Heterogeneous vancomycin-intermediate <i>Staphylococcus aureus</i> (hVISA) 8
1.5 抗生素作用機制 9	1.5.1 抑制細胞壁合成 9
1.5.2 破壞細胞膜 10	1.5.3 影響蛋白質合成 10
1.5.4 抑制核酸形成 10	1.6 細菌抗藥機制 11
1.6.1 分解抗生素或使之失去活性 11	1.6.2 改變抗生素作用標的 12
1.6.3 阻礙抗生素進入或主動排出抗生素 12	1.7 MRSA抗藥機制 13
1.8 研究動機 13	2. 材料與方法 14
2.1 菌株來源與保存 15	2.2 菌株檢定 15
2.2.1 DNA 抽取 15	2.2.1 Multiplex PCR 16
2.2.2 Staphylococcal cassette chromosome mec (SCCmec)檢測 16	2.2.2.1 Verification of type VT 16
2.2.2.2 CoNS 16	2.2.2.3 Multilocus sequencing typing (MLST) 17
2.2.2.4 Pantone-Valentine leukocidin(PVL)基因檢測 19	2.3 Minimum inhibitory concentration(MIC)與抗藥性測試 19
2.3.1 以E-test方法測定MIC 19	2.3.2 異質hetero-VISA測試 20
2.3.3 異質hetero-VISA測試結果 20	3. 實驗結果 3.1 菌株檢定 22
3.1.1 SCCmec 檢測結果 22	3.1.2 PVL基因檢測結果 23
3.1.3 MLST檢測結果 23	3.2 MIC 與抗藥性測試結果 24
3.2.1 MRSA MIC結果 24	3.2.2 異質hetero-VISA 測試結果 24
3.2.3 MSSA MIC結果 25	3.2.4 CoNS MIC結果 25
3.2.5 ST45與ST59對Ciprofloxacin之MIC值 25	

REFERENCES

2009. Classification of staphylococcal cassette chromosome mec (SCCmec): guidelines for reporting novel SCCmec elements. *Antimicrobial agents and chemotherapy*. 53:4961-4967.
2. Austin, D.J., K.G. Kristinsson, and R.M. Anderson. 1999. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. *Proceedings of the National Academy of Sciences of the United States of America*. 96:1152-1156.
3. Bennett, J.W., C.K. Murray, R.L. Holmes, J.E. Patterson, and J.H. Jorgensen. 2008. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant *Staphylococcus aureus*. *Diagnostic microbiology and infectious disease*. 60:437-440.
4. Boucher, H.W., G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, M. Scheld, B. Spellberg, and J. Bartlett. 2009. Bad bugs, no drugs: no ESCAPE! An update from the Infectious Diseases Society of America. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 48:1-12.
5. Boyle-Vavra, S., B. Ereshefsky, C.C. Wang, and R.S. Daum. 2005. Successful multiresistant community-associated methicillin-resistant *Staphylococcus aureus* lineage from Taipei, Taiwan, that carries either the novel *Staphylococcal chromosome cassette mec (SCCmec)* type VT or SCCmec type IV. *Journal of clinical microbiology*. 43:4719-4730.
6. Campanile, F., S. Borbone, M. Perez, D. Bongiorno, V. Cafiso, T. Bertuccio, S. Purrello, D. Nicolosi, C. Scuderi, and S. Stefani. 2010. Heteroresistance to glycopeptides in Italian methicillin-resistant *Staphylococcus aureus* (MRSA) isolates. *International journal of antimicrobial agents*. 36:415-419.
7. Center, K.J., A.C. Reboli, R. Hubler, G.L. Rodgers, and S.S. Long. 2003. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of *Staphylococcus warneri*. *Journal of clinical microbiology*. 41:4660-4665.
8. Chang, S.C., W.C. Hsieh, and C.Y. Liu. 2000. High prevalence of antibiotic resistance of common pathogenic bacteria in Taiwan. The Antibiotic Resistance Study Group of the Infectious Disease Society of the Republic of China. *Diagnostic microbiology and infectious disease*. 36:107-112.
9. Chen, C.J., and Y.C. Huang. 2005. Community-acquired methicillin-resistant *Staphylococcus aureus* in Taiwan. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi*. 38:376-382.
10. Chen, F.J., I.W. Huang, C.H. Wang, P.C. Chen, H.Y. Wang, J.F. Lai, Y.R. Shiau, and T.L. Lauderdale. 2012. *mecA*-positive *Staphylococcus aureus* with low-level oxacillin MIC in Taiwan. *Journal of clinical microbiology*. 50:1679-1683.
11. Chen, F.J., T.L. Lauderdale, I.W. Huang, H.J. Lo, J.F. Lai, H.Y. Wang, Y.R. Shiau, P.C. Chen, T. Ito, and K. Hiramatsu. 2005. Methicillin-resistant *Staphylococcus aureus* in Taiwan. *Emerging infectious diseases*. 11:1760-1763.
12. Chuang, C.Y., Y.L. Yang, P.R. Hsueh, and P.I. Lee. 2010. Catheter-related bacteremia caused by *Staphylococcus pseudintermedius* refractory to antibiotic-lock therapy in a hemophilic child with dog exposure. *Journal of clinical microbiology*. 48:1497-1498.
13. D'Souza, N., A. Shetty, A. Mehta, and C. Rodrigues. 2010. Antimicrobial susceptibility profiles of methicillin-susceptible and -resistant *Staphylococcus aureus*: focus on daptomycin minimum inhibitory concentrations at a tertiary care centre in Mumbai, India. *International journal of antimicrobial agents*. 36:267-270.
14. Deurenberg, R.H., E. Nulens, H. Valvatne, S. Sebastian, C. Driessen, J. Craeghs, E. De Brauwier, B. Heising, Y.J. Kraat, J. Riebe, F.S. Stals, T.A. Trienekens, J. Scheres, A.W. Friedrich, F.H. van Tiel, P.S. Beisser, and E.E. Stobberingh. 2009. Cross-border dissemination of methicillin-resistant *Staphylococcus aureus*, Euregio Meuse-Rhin region. *Emerging infectious diseases*. 15:727-734.
15. Deurenberg, R.H., and E.E. Stobberingh. 2008. The evolution of *Staphylococcus aureus*. *Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases*. 8:747-763.
16. Diekema, D.J., M.A. Pfaller, F.J. Schmitz, J. Smayevsky, J. Bell, R.N. Jones, and M. Beach. 2001. Survey of infections due to *Staphylococcus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 32 Suppl 2:S114-132.
17. Diep, B.A., and M. Otto. 2008. The role of virulence determinants in community-associated MRSA pathogenesis. *Trends in microbiology*. 16:361-369.
18. Enright, M.C., N.P. Day, C.E. Davies, S.J. Peacock, and B.G. Spratt. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. *Journal of clinical microbiology*. 38:1008-1015.
19. Feng, Y., C.J. Chen, L.H. Su, S. Hu, J. Yu, and C.H. Chiu. 2008. Evolution and pathogenesis of *Staphylococcus aureus*: lessons learned from genotyping and comparative genomics. *FEMS microbiology reviews*. 32:23-37.
20. Fischbach, M.A., and C.T. Walsh. 2009. Antibiotics for emerging pathogens. *Science*. 325:1089-1093.
21. Foster, T.J. 2005. Immune evasion by staphylococci. *Nature reviews. Microbiology*. 3:948-958.
22. Gorwitz, R.J. 2008. A review of community-associated methicillin-resistant *Staphylococcus aureus* skin and soft tissue infections. *The Pediatric infectious disease journal*. 27:1-7.
23. Hanssen, A.M., and J.U. Ericson Sollid. 2006. SCCmec in staphylococci: genes on the move. *FEMS immunology and medical microbiology*. 46:8-20.
24. Higuchi, W., T. Takano, L.J. Teng, and T. Yamamoto. 2008. Structure and specific detection of staphylococcal cassette chromosome mec type VII. *Biochemical and biophysical research communications*. 377:752-756.
25. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F.C. Tenover. 1997. Methicillin-resistant *Staphylococcus aureus* clinical strain with reduced vancomycin susceptibility. *The Journal of antimicrobial chemotherapy*. 40:135-136.
26. Ho, M., L.C. McDonald, T.L. Lauderdale, L.L. Yeh, P.C. Chen, and Y.R. Shiau. 1999. Surveillance of antibiotic resistance in Taiwan, 1998. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi*. 32:239-249.
27. Howden, B.P., P.D. Johnson, P.G. Charles, and M.L. Grayson. 2004. Failure of vancomycin for treatment of methicillin-resistant *Staphylococcus aureus* infections. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 39:1544; author reply 1544-1545.
28. Howden, B.P., P.D.

Johnson, P.B. Ward, T.P. Stinear, and J.K. Davies. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant *Staphylococcus aureus*. bacteremia. *Antimicrobial agents and chemotherapy*. 50:3039-3047. 29.Huang, Y.C., C.F. Ho, C.J. Chen, L.H. Su, and T.Y. Lin. 2008a. Comparative molecular analysis of community-associated and healthcare-associated methicillin-resistant *Staphylococcus aureus*. isolates from children in northern Taiwan. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 14:1167-1172. 30.Huang, Y.C., L.H. Su, T.L. Wu, C.E. Liu, T.G. Young, P.Y. Chen, P.R. Hseuh, and T.Y. Lin. 2004. Molecular epidemiology of clinical isolates of methicillin-resistant *Staphylococcus aureus*. in Taiwan. *Journal of clinical microbiology*. 42:307-310. 31.Huang, Y.T., C.H. Hsiao, C.H. Liao, C.W. Lee, and P.R. Hsueh. 2008b. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant *Staphylococcus aureus*. strain in Taiwan. *Journal of clinical microbiology*. 46:1132-1136. 32.Hung, W.C., T. Takano, W. Higuchi, Y. Iwao, O. Khokhlova, L.J. Teng, and T. Yamamoto. 2012. Comparative genomics of community-acquired ST59 methicillin-resistant *Staphylococcus aureus*. in Taiwan: novel mobile resistance structures with IS1216V. *PloS one*. 7:e46987. 33.Ito, T., Y. Katayama, K. Asada, N. Mori, K. Tsutsumimoto, C. Tiensasitorn, and K. Hiramatsu. 2001. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant *Staphylococcus aureus*. *Antimicrobial agents and chemotherapy*. 45:1323-1336. 34.Jessen, O., K. Rosendal, P. Bulow, V. Faber, and K.R. Eriksen. 1969. Changing staphylococci and staphylococcal infections. A ten-year study of bacteria and cases of bacteremia. *The New England journal of medicine*. 281:627-635. 35.Kluytmans-Vandenberg, M.F., and J.A. Kluytmans. 2006. Community-acquired methicillin-resistant *Staphylococcus aureus*: current perspectives. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 12 Suppl 1:9-15. 36.Kluytmans, J., A. van Belkum, and H. Verbrugh. 1997. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clinical microbiology reviews*. 10:505-520. 37.Labandeira-Rey, M., F. Couzon, S. Boisset, E.L. Brown, M. Bes, Y. Benito, E.M. Barbu, V. Vazquez, M. Hook, J. Etienne, F. Vandenesch, and M.G. Bowden. 2007. *Staphylococcus aureus*. Panton-Valentine leukocidin causes necrotizing pneumonia. *Science*. 315:1130-1133. 38.Lin, S.Y., T.C. Chen, F.J. Chen, Y.H. Chen, Y.I. Lin, L. Kristopher Siu, and P.L. Lu. 2012. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate *Staphylococcus aureus*. bacteremia in a Taiwan Medical Center. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi*. 39.Lina, G., Y. Piemont, F. Godail-Gamot, M. Bes, M.O. Peter, V. Gauduchon, F. Vandenesch, and J. Etienne. 1999. Involvement of Panton-Valentine leukocidin-producing *Staphylococcus aureus*. in primary skin infections and pneumonia. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 29:1128-1132. 40.Llarrull, L.I., J.F. Fisher, and S. Mobashery. 2009. Molecular basis and phenotype of methicillin resistance in *Staphylococcus aureus*. and insights into new beta-lactams that meet the challenge. *Antimicrobial agents and chemotherapy*. 53:4051-4063. 41.McDonald, L.C., T.L. Lauderdale, Y.R. Shiau, P.C. Chen, J.F. Lai, H.Y. Wang, and M. Ho. 2004. The status of antimicrobial resistance in Taiwan among Gram-positive pathogens: the Taiwan Surveillance of Antimicrobial Resistance (TSAR) programme, 2000. *International journal of antimicrobial agents*. 23:362-370. 42.Mombach Pinheiro Machado, A.B., K.C. Reiter, R.M. Paiva, and A.L. Barth. 2007. Distribution of staphylococcal cassette chromosome mec (SCCmec) types I, II, III and IV in coagulase-negative staphylococci from patients attending a tertiary hospital in southern Brazil. *Journal of medical microbiology*. 56:1328-1333. 43.Monecke, S., G. Coombs, A.C. Shore, D.C. Coleman, P. Akpaka, M. Borg, H. Chow, M. Ip, L. Jatzwauk, D. Jonas, K. Kadlec, A. Kearns, F. Laurent, F.G. O'Brien, J. Pearson, A. Ruppelt, S. Schwarz, E. Scicluna, P. Slickers, H.L. Tan, S. Weber, and R. Ehrlich. 2011. A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant *Staphylococcus aureus*. *PloS one*. 6:e17936. 44.Monnet, D.L., F.M. MacKenzie, J.M. Lopez-Lozano, A. Beyaert, M. Camacho, R. Wilson, D. Stuart, and I.M. Gould. 2004. Antimicrobial drug use and methicillin-resistant *Staphylococcus aureus*. Aberdeen, 1996-2000. *Emerging infectious diseases*. 10:1432-1441. 45.Moran, G.J., A. Krishnadasan, R.J. Gorwitz, G.E. Fosheim, L.K. McDougal, R.B. Carey, and D.A. Talan. 2006. Methicillin-resistant *S. aureus* infections among patients in the emergency department. *The New England journal of medicine*. 355:666-674. 46.Musta, A.C., K. Riederer, S. Shemes, P. Chase, J. Jose, L.B. Johnson, and R. Khatib. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant *Staphylococcus aureus*. bacteremia: trends over 11 years. *Journal of clinical microbiology*. 47:1640-1644. 47.Natoli, S., C. Fontana, M. Favaro, A. Bergamini, G.P. Testore, S. Minelli, M.C. Bossa, M. Casapulla, G. Broglio, A. Beltrame, L. Cudillo, R. Cerretti, and F. Leonardi. 2009. Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options. *BMC infectious diseases*. 9:83. 48.Noskin, G.A., R.J. Rubin, J.J. Schentag, J. Kluytmans, E.C. Hedblom, M. Smulders, E. Lapetina, and E. Gemmen. 2005. The burden of *Staphylococcus aureus*. infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. *Archives of internal medicine*. 165:1756-1761. 49.Okuma, K., K. Iwakawa, J.D. Turnidge, W.B. Grubb, J.M. Bell, F.G. O'Brien, G.W. Coombs, J.W. Pearman, F.C. Tenover, M. Kapi, C. Tiensasitorn, T. Ito, and K. Hiramatsu. 2002. Dissemination of new methicillin-resistant *Staphylococcus aureus*. clones in the community. *Journal of clinical microbiology*. 40:4289-4294. 50.Oliveira, D.C., and H. de Lencastre. 2002. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant *Staphylococcus aureus*. *Antimicrobial agents and chemotherapy*. 46:2155-2161. 51.Oztoprak, N., M.A. Cevik, E. Akinci, M. Korkmaz, A. Erbay, S.S. Eren, N. Balaban, and H. Bodur. 2006. Risk factors for ICU-acquired methicillin-resistant *Staphylococcus aureus*. infections. *American journal of infection control*. 34:1-5. 52.Peterson, L.R. 2009. Bad bugs, no drugs: no ESCAPE revisited. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 49:992-993. 53.Rybak, M.J., S.N. Leonard, K.L. Rossi, C.M. Cheung, H.S. Sader, and R.N. Jones. 2008. Characterization of vancomycin-heteroresistant *Staphylococcus aureus*. from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). *Journal*

of clinical microbiology. 46:2950-2954. 54.Sader, H.S., and R.N. Jones. 2012. Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus. *Diagnostic microbiology and infectious disease*. 73:212-214. 55.Saiman, L., M. O'Keefe, P.L. Graham, 3rd, F. Wu, B. Said-Salim, B. Kreiswirth, A. LaSala, P.M. Schlievert, and P. Della-Latta. 2003. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus. among postpartum women. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 37:1313-1319. 56.Sakoulas, G., P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellering, Jr., and G.M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus. bacteremia. *Journal of clinical microbiology*. 42:2398-2402. 57.Shinabarger, D.L., K.R. Marotti, R.W. Murray, A.H. Lin, E.P. Melchior, S.M. Swaney, D.S. Dunyak, W.F. Demyan, and J.M. Buysse. 1997. Mechanism of action of oxazolidinones: effects of linezolid and eperzolid on translation reactions. *Antimicrobial agents and chemotherapy*. 41:2132-2136. 58.Tenover, F.C., and R.C. Moellering, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 44:1208-1215. 59.Traczewski, M.M., B.D. Katz, J.N. Steenbergen, and S.D. Brown. 2009. Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus. isolates collected from 1985 to 2007. *Antimicrobial agents and chemotherapy*. 53:1735-1738. 60.Tseng, C.W., P. Kyme, J. Low, M.A. Rocha, R. Alsabeh, L.G. Miller, M. Otto, M. Arditi, B.A. Diep, V. Nizet, T.M. Doherty, D.O. Beenhouwer, and G.Y. Liu. 2009. Staphylococcus aureus. Panton-Valentine leukocidin contributes to inflammation and muscle tissue injury. *PloS one*. 4:e6387. 61.van Hal, S.J., and D.L. Paterson. 2011. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus. isolates. *Antimicrobial agents and chemotherapy*. 55:405-410. 62.Wang, F.D., Y.Y. Chen, T.L. Chen, and C.Y. Liu. 2008. Risk factors and mortality in patients with nosocomial Staphylococcus aureus. bacteremia. *American journal of infection control*. 36:118-122. 63.Wang, L., Y. Liu, Y. Yang, G. Huang, C. Wang, L. Deng, Y. Zheng, Z. Fu, C. Li, Y. Shang, C. Zhao, M. Sun, X. Li, S. Yu, K. Yao, and X. Shen. 2012a. Multidrug-resistant clones of community-associated methicillin-resistant Staphylococcus aureus. isolated from Chinese children and the resistance genes to clindamycin and mupirocin. *Journal of medical microbiology*. 61:1240-1247. 64.Wang, R., K.R. Braughton, D. Kretschmer, T.H. Bach, S.Y. Queck, M. Li, A.D. Kennedy, D.W. Dorward, S.J. Klebanoff, A. Peschel, F.R. DeLeo, and M. Otto. 2007. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. *Nature medicine*. 13:1510-1514. 65.Wang, W.Y., T.S. Chiueh, J.R. Sun, S.M. Tsao, and J.J. Lu. 2012b. Molecular typing and phenotype characterization of methicillin-resistant Staphylococcus aureus. isolates from blood in Taiwan. *PloS one*. 7:e30394. 66.Zetola, N., J.S. Francis, E.L. Nuermberger, and W.R. Bishai. 2005. Community-acquired methicillin-resistant Staphylococcus aureus.: an emerging threat. *The Lancet infectious diseases*. 5:275-286